Almac Group’s Comprehensive Service Offerings to Support Expedited COVID-19 Research Programs & Treatments

Almac Group is an established contract development and manufacturing organization (CDMO) providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.

As the global Coronavirus crisis continues to escalate, Almac has commenced work on supporting 34 (and counting) separate crucial research projects into COVID-19 treatment options for a variety of global pharmaceutical, biotech and research institutions.  We are supporting this urgent research need through a range of services, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support, and clinical trial manufacturing, packaging, and distribution.

A highlight of our solutions that are currently supporting COVID-19 related research programs is below:

Almac offers two distribution models, Direct-to-Patient via Site (DTP) and Almac-to-Patient (ATP).

Direct-to-Patient Via Site
Almac’s Direct-to-Patient via Site model ensures continuity of drug supply to the patient’s home. Almac has an established DTP via Site distribution service providing for patients that have critical needs. Given Covid-19 and the acceleration of this pandemic, increasing numbers of patients cannot travel to site due to Government restrictions on movements so Almac is facilitating site to patient deliveries globally.

If site has closed or key staff is no longer able to travel to a site due to an increase in restrictions and lockdowns, our Almac-to-Patient solution may be utilized. Almac can ship supplies directly to the patient’s home from an Almac facility, all whilst upholding GXP compliance. With project management and courier services combined, Almac is uniquely positioned to remove the obstacles to the delivery of essential clinical supplies to your patients.

Full late-stage customization of clinical supplies by postponing packaging and labeling until the site or patient need arises.

End-to-end regulatory compliant solution that gives full visibility of temperature data from any stakeholder within your supply chain.

In response to COVID-19, Almac now offers an expedited process to design, validate, and deploy fully functioning IRT systems used for patient randomization and clinical trial material management in as little as 1 week, depending on protocol complexity.

A unified clinical trial solution that integrates patient recruitment, clinical supply, and IRT strategies with closed-loop technology to enable a holistic data flow that leverages insights to provide greater flexibility and visibility over your clinical supply.

Over 20 years of experience supplying peptides to both the research community and for clinical trials. Our team of experts have developed a high level of technical expertise enabling peptide manufacture, peptides with a wide range of complexity, including high-throughput manufacture, long peptides, conjugation, and peptide cocktails.

A key player in the area of biocatalyst research, development, and commercial supply of biocatalytically derived achiral and chiral products at multi-tonne scale. Our expertise ranges from enzyme discovery, engineering, and screening, to the enzyme applied synthesis of complex chiral products, all based on Almac’s selectAZymeTM technology.

Offering a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances from our labs across UK, Europe, and US. Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past 5 decades now employing over 5,600 highly skilled personnel across 18 facilities, including Europe, the US, and Asia.

To keep up to date with latest news, follow Almac Group on Twitter and LinkedIn or visit